# South America Brucellosis Market > South America Brucellosis Market Research Report By species (Brucella suis, B. abortus, B. melitensis) and By Regional (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.97% - **2024:** $ 32.88 Million - **2025:** $ 35.17 Million - **2035:** $ 69.01 Million - **Key Players:** Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim GmbH (DE), Ceva Santé Animale (FR), Vetoquinol SA (FR), Heska Corporation (US), Elanco Animal Health Incorporated (US), Virbac SA (FR) **Report ID:** MRFR/LS/51834-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-brucellosis-market-53595 --- ## Market Summary ## **South America Brucellosis Market Overview** As per MRFR analysis, the South America Brucellosis Market Size was estimated at 14.23 (USD Million) in 2023.The South America Brucellosis Market is expected to grow from 15.5(USD Million) in 2024 to 40.6 (USD Million) by 2035. The South America Brucellosis Market CAGR (growth rate) is expected to be around 9.148% during the forecast period (2025 - 2035). **Key South America Brucellosis Market Trends Highlighted** Numerous significant market factors are influencing the South American brucellosis market and reshaping its environment. The growing knowledge of zoonotic illnesses among consumers and health authorities is one important motivator. Stronger laws and health initiatives to prevent brucellosis in livestock have resulted from this increased awareness, especially in nations like Brazil and Argentina where the livestock sector is essential to the national economy. Additionally, increased funding for veterinary care and immunization campaigns is improving disease prevention and guaranteeing a strong response to outbreaks of brucellosis. The developing cattle industry and the rising demand for animal products present opportunities in the South American brucellosis market. There is a push for better animal health and biosecurity controls as nations work toward sustainable farming methods. This tendency is especially apparent in areas where goat and cow rearing are common, giving market participants the chance to launch cutting-edge vaccines and diagnostic equipment. Increasingly integrated approaches to disease management, combining vaccination with farmer education programs, have been increasingly prevalent in the South American brucellosis market in recent years. Training programs that teach optimal methods for handling livestock and animal health are being aggressively promoted by governments. Additionally, in an effort to better understand the dynamics of brucellosis transmission, research partnerships involving public health organizations and commercial sector players are beginning to take shape. In order to control and eventually lower the disease's prevalence, which promotes a healthier livestock population and increased food security throughout the region, such cooperative efforts are essential. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Brucellosis Market Drivers** **Growing Livestock Population** The livestock sector in South America has experienced a significant increase, which is a major driver for the South America [Brucellosis Market](../../../reports/brucellosis-market-5159). With countries like Brazil being one of the largest producers of beef and cattle globally, the livestock population plays a crucial role in the prevalence of zoonotic diseases such as brucellosis. According to a recent report from the Brazilian Institute of Geography and Statistics, the livestock population in Brazil reached approximately 218 million head of cattle. This growing population is likely to contribute to higher incidences of brucellosis, thereby increasing the demand for vaccines and diagnostic tools to combat the disease. Organizations such as the Food and Agriculture Organization of the United Nations (FAO) and the Pan American Health Organization (PAHO) emphasize the economic impact of brucellosis outbreaks in livestock, marking it as a public health concern. Thus, the expanding livestock sector is pivotal to understanding the growth trajectory of the South America Brucellosis Market. **Increased Awareness and Preventive Measures** There has been a growing awareness of brucellosis among farmers and the general public in South America, particularly in rural areas where livestock is a primary source of income. Initiatives led by health and agricultural departments in countries like Argentina and Colombia aim to educate farmers on the risks associated with brucellosis and the importance of vaccination programs. According to the Ministry of Agriculture in Argentina, there has been a notable increase of up to 35% in vaccination coverage among livestock in recent years. This heightened awareness translates into a rising demand for brucellosis vaccines and diagnostic tests, further propelling the South America Brucellosis Market. The collaboration with organizations such as the World Organization for Animal Health (OIE) helps bolster these preventive measures, promoting health and safeguarding the livelihoods of farmers. **Government Initiatives and Funding** Government policies aimed at controlling and preventing brucellosis outbreaks in livestock significantly influence the South America Brucellosis Market. Several countries in South America are implementing national strategic plans for the control of brucellosis. For example, the Ministry of Agriculture in Brazil reported the allocation of over USD 5 million towards research and control programs for livestock diseases, including brucellosis. Funding from governmental bodies aids in the development of vaccines, diagnostic tools, and public awareness campaigns, thus creating a conducive environment for the market's expansion. Multi-agency efforts also involve collaboration with the World Health Organization (WHO) to align animal health with public health, which further stimulates market growth. **Rising Incidence of Zoonotic Diseases** The increased prevalence of zoonotic diseases, including brucellosis, has become a pressing concern in South America. Zoonotic diseases, which can be transmitted from animals to humans, pose significant public health risks, particularly in rural communities that rely heavily on animal husbandry. The World Health Organization (WHO) estimates that approximately 500,000 cases of brucellosis occur globally each year, with a significant proportion concentrated in developing countries like those in South America. This alarming statistic underscores the need for enhanced disease management strategies, leading to an upsurge in demand for brucellosis vaccines and diagnostic testing. With national health organizations and governments prioritizing the control of zoonoses, the ramifications directly enhance the prospects of the South America Brucellosis Market. **South America Brucellosis Market Segment Insights** **Brucellosis Market species Insights** The South America Brucellosis Market has shown a notable development concerning species segmentation, primarily focusing on Brucella suis, B. abortus, and B. melitensis. Among these species, B. abortus holds a prominent place as it primarily affects cattle, which are integral to the agricultural economy in South America. The prevalence of this species has made it a critical target for disease management and control initiatives. Furthermore, the economic impact attributed to B. melitensis, which primarily affects sheep and goats, is significant as well, considering the importance of these livestock in the region's meat and dairy production. The agricultural practices and livestock management in South America contribute to the presence of these pathogenic species, thereby underlining the necessity for robust vaccination and diagnostic strategies. B. suis, while less prevalent compared to the other two, remains noteworthy due to its impact on pigs, which are increasingly becoming important in various South American countries. All three species indicate a growing concern among veterinarians and livestock owners regarding the economic burdens of brucellosis, which leads to production losses and trade restrictions. The complexity of controlling these brucellosis cases across species creates opportunities for innovative diagnostics and vaccines in the South American Brucellosis Market. As the local governments and agricultural bodies continue to invest in disease prevention strategies, understanding the dynamics of these species becomes essential for addressing brucellosis-related challenges effectively. The rise of zoonotic diseases in the region has also pushed this agenda further, prompting a call for enhanced public health surveillance alongside veterinary health initiatives. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Brucellosis Market Regional Insights** The South America Brucellosis Market showcases significant growth potential, particularly within its Regional segment, encompassing Brazil, Mexico, Argentina, and the Rest of South America. Brazil stands as a crucial player in this market, with its large livestock population making it a key area for brucellosis management and control. Mexico, too, has a noteworthy role due to its agricultural sector, which faces challenges from this disease, impacting both health and economic productivity. Argentina, with its extensive cattle farming industry, confronts the effects of brucellosis, thus prioritizing vaccine development and animal health initiatives. The Rest of South America includes several countries where brucellosis remains a concern, prompting governments to enhance surveillance and preventive measures to safeguard livestock health. The market dynamics in this region are influenced by various factors, such as rising concerns over animal health, increased investment in veterinary healthcare services, and collaboration among agricultural stakeholders for brucellosis eradication efforts. The governmental policies aiming to mitigate disease outbreaks further emphasize the significance of this segment in ensuring food safety and economic stability across the region. Efforts to educate farmers about prevention and control methods also play a pivotal role in shaping the future of the South America Brucellosis Market, leading to improved livestock management practices. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Brucellosis Market Key Players and Competitive Insights** The South America Brucellosis Market is characterized by its competitive landscape, primarily shaped by the presence of key players engaged in developing innovative vaccination solutions and diagnostic tests for brucellosis. The market dynamics are influenced by the rising demand for effective control measures against the disease, which significantly impacts both livestock productivity and public health in the region. A variety of companies are focusing on strengthening their market positions through strategic collaborations and advancements in research and development, aimed at providing comprehensive solutions tailored for local agricultural practices. The market is also witnessing heightened regulatory scrutiny, encouraging firms to comply with stringent health guidelines while enhancing their product offerings to gain a competitive edge. Elanco stands out in the South America Brucellosis Market due to its robust portfolio of animal health products specifically designed to combat infectious diseases. The company’s strengths lie in its commitment to research and the development of effective vaccines that cater to regional livestock needs. Elanco's established presence in South America is further bolstered by its strong distribution networks and relationships with local farmers and veterinarians, allowing it to maintain a significant market share. The focus on customer engagement and education regarding disease prevention strategies contributes to Elanco's reputable standing in the market, enabling it to respond effectively to the challenges posed by brucellosis outbreaks in various countries across the region. Ceva Sante Animale plays a crucial role in the South America Brucellosis Market, offering a range of vaccines and diagnostic products aimed at preventing the spread of the disease among livestock. The company has successfully capitalized on its extensive research capabilities and localized strategies to create effective solutions that meet the needs of farmers in South America. Ceva's strengths are reinforced by regular investments in innovative technologies and collaborations with local authorities, enhancing its ability to provide reliable products that address regional health concerns. Additionally, Ceva Sante Animale has been active in pursuing mergers and acquisitions to expand its reach and strengthen its market position, solidifying its presence in the South American agricultural landscape and fostering partnerships that promote the adoption of its solutions for brucellosis control. **Key Companies in the South America Brucellosis Market Include** - Elanco - Ceva Sante Animale - Vetoquinol - Heska Corporation - Merck Animal Health - AgriLabs - Boehringer Ingelheim - Virbac - Cegelec - Zoetis - Hygieia **South America Brucellosis****Market****Developments** The South America Brucellosis Market is witnessing significant developments, marked by heightened awareness and control measures across the region. The Brazilian government has intensified vaccination campaigns against Brucellosis to enhance livestock health and productivity, leading to enhanced market stability. Elanco continues to focus on the effectiveness of its vaccine solutions in combating livestock diseases, while Ceva Sante Animale is launching new brucellosis vaccination programs aimed at improving dairy cattle health in Argentina. In terms of mergers and acquisitions, Zoetis announced the acquisition of a leading South American animal health company in July 2023, a move aimed at bolstering its position in the region's brucellosis market. Additionally, Boehringer Ingelheim's recent collaboration with local agricultural agencies in Colombia, reported in September 2023, highlights the company’s dedication to addressing livestock diseases. The overall market value for companies like Merck Animal Health and Virbac has seen an upward trajectory due to increased livestock health initiatives, with a growing demand for effectively managing Brucellosis impacting the landscape of South America's animal health industry significantly. **South America Brucellosis Market Segmentation Insights** **Brucellosis Market species Outlook** - Brucella suis - B. abortus - B. melitensis **Brucellosis Market Regional Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Rising Incidence of Brucellosis The increasing incidence of brucellosis in South America is a critical driver for the brucellosis market. Reports indicate that the prevalence of this zoonotic disease has been on the rise, particularly in rural areas where livestock farming is prevalent. The World Health Organization has noted that brucellosis affects thousands of individuals annually, leading to significant health concerns. This situation compels governments and health organizations to invest in better diagnostic and treatment options, thereby stimulating growth in the brucellosis market. Furthermore, the economic burden associated with brucellosis, estimated at millions of dollars annually, underscores the need for effective control measures and healthcare interventions, which could further enhance market dynamics. ### Increased Awareness and Education There is a growing awareness regarding brucellosis among both the public and healthcare professionals in South America. Educational campaigns aimed at informing farmers and livestock handlers about the risks associated with brucellosis are becoming more prevalent. This heightened awareness is likely to lead to increased demand for diagnostic tests and vaccines, thereby driving the brucellosis market. As more individuals recognize the symptoms and transmission routes of the disease, they are more inclined to seek medical attention and preventive measures. Consequently, this trend may result in a more proactive approach to managing brucellosis, which could significantly impact market growth and development in the region. ### Government Initiatives and Funding Government initiatives aimed at controlling zoonotic diseases, including brucellosis, are pivotal in shaping the brucellosis market. In South America, various governments have allocated funding for research and development of vaccines and diagnostic tools. For instance, initiatives to enhance surveillance and reporting systems for brucellosis cases are being implemented. Such government support not only facilitates advancements in medical technology but also encourages private sector investment in the brucellosis market. The financial backing from public health agencies is expected to bolster the development of innovative solutions, thereby addressing the challenges posed by brucellosis and enhancing overall market potential. ### Advancements in Veterinary Medicine Advancements in veterinary medicine are significantly impacting the brucellosis market in South America. Innovations in vaccine development and diagnostic technologies are enhancing the ability to control and prevent brucellosis in livestock. The introduction of more effective vaccines and rapid diagnostic tests is likely to improve disease management strategies among farmers and veterinarians. As these advancements become more accessible, they may lead to increased adoption rates among livestock producers, thereby driving demand in the brucellosis market. Furthermore, the integration of veterinary services with public health initiatives could foster a more comprehensive approach to managing brucellosis, ultimately benefiting both animal and human health. ### Livestock Trade and Economic Factors The livestock trade in South America plays a significant role in the dynamics of the brucellosis market. As the demand for meat and dairy products continues to rise, the risk of brucellosis transmission among livestock increases. This situation necessitates stringent health measures and monitoring systems to prevent outbreaks, which in turn drives the market for brucellosis diagnostics and vaccines. Economic factors, such as fluctuations in livestock prices and trade agreements, also influence the market. For instance, a decline in livestock health due to brucellosis can lead to substantial economic losses, prompting stakeholders to invest in preventive measures and treatments, thereby stimulating market growth. ## Future Outlook The [Brucellosis Market](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) is projected to grow at a 6.97% CAGR from 2025 to 2035, driven by increased awareness, improved diagnostics, and enhanced vaccination programs. **New opportunities:** - Development of mobile diagnostic units for remote areas - Investment in advanced vaccine research and production - Partnerships with agricultural sectors for disease management solutions By 2035, the market is expected to achieve substantial growth, driven by innovative strategies and partnerships. ## Segment Insights ### By Species: Brucella abortus (Largest) vs. Brucella melitensis (Fastest-Growing) In the species segment, Brucella abortus holds the largest market share due to its dominance in livestock populations, particularly in cattle. This bacterium is a significant concern for farmers and veterinarians alike, leading to heightened awareness and control measures. Following closely is Brucella melitensis, which, while having a smaller market share, is gaining traction due to increased incidences associated with goats and sheep, which are prevalent in many regions of South America. Furthermore, Brucella suis, Brucella canis, and others contribute to the market but do not match the prominence of these two strains. The growth trends in this segment indicate a notable increase in awareness and preventative measures against brucellosis, driven by rising livestock trade and the demand for safe meat products. Governments and health organizations are focusing on educational campaigns to mitigate brucellosis outbreaks. This is particularly evident with Brucella melitensis, which is being recognized for its emergence as a public health concern, leading to increased funding for research and vaccination programs aimed at controlling its spread in rural communities. Brucella abortus (Dominant) vs. Brucella melitensis (Emerging) Brucella abortus is established as the dominant species in the segment, primarily affecting cattle and leading to significant economic losses in the agricultural sector. Its prevalence encourages stringent control measures, including vaccination and testing practices. In contrast, Brucella melitensis is emerging rapidly, particularly in small ruminants like goats and sheep. This emergence is fueled by increased urbanization and the associated rise in animal-human interactions, raising awareness of the risks it poses to human health. As a result, there is a growing emphasis on monitoring and controlling Brucella melitensis, making it a key focus area for research and public health initiatives. ### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing) In the Diagnosis segment, serological tests hold a significant portion of the market share as the primary method for detecting brucellosis. These tests have been widely adopted due to their cost-effectiveness and ease of implementation. In contrast, molecular techniques are gaining traction, particularly as advancements in technology enhance their sensitivity and specificity, making them crucial for accurate diagnosis. Growth in the Diagnosis segment is driven by increasing awareness and better healthcare access across South America. The rising prevalence of brucellosis due to livestock interactions necessitates efficient diagnostic solutions. Molecular techniques are noted as the fastest-growing category, propelled by the demand for precise diagnostic methods that can expedite treatment and reduce disease transmission rates, thereby improving public health outcomes. Serological Tests (Dominant) vs. Molecular Techniques (Emerging) Serological tests are acknowledged as the dominant technique for diagnosing brucellosis, favored for their simplicity and low cost, making them accessible for use in various healthcare settings. They primarily detect antibodies in the blood, which are indicative of an infection. On the other hand, molecular techniques, while currently emerging, are rapidly evolving and provide a more precise approach by identifying the genetic material of Brucella bacteria. This method offers quicker results and more reliable data, catering to the growing demand for advanced diagnostic solutions that can aid in timely intervention and management of the disease. ### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing) In the South America brucellosis market, the treatment segment is primarily dominated by antibiotics, which hold a significant market share due to their well-established efficacy in treating brucellosis in livestock. Vaccines, while smaller in overall share, are gaining traction as awareness of their preventive benefits continues to rise among farmers and veterinarians. The combined appeal of these treatment options is critical for addressing the disease's impact on the agricultural sector. Growth trends indicate a robust expansion in the vaccine segment, propelled by advancements in vaccine technology and increasing emphasis on prevention over treatment. Factors driving this shift include heightened regulatory measures, improved herd health management practices, and a growing recognition of the economic advantages of vaccination. As the market evolves, the focus on antibiotics remains strong, but the emergence of vaccines as a preferred option for disease management is clear. Antibiotics (Dominant) vs. Vaccines (Emerging) Antibiotics are the dominant force in the treatment segment, favored for their immediate efficacy in combating active brucellosis infections. Their extensive use and established protocols ensure they remain a staple in livestock health management. On the other hand, vaccines are rapidly emerging as a critical alternative, focusing on disease prevention rather than treatment. The growing adoption of vaccination strategies highlights a shift in market dynamics that emphasizes long-term herd health and profitability. Both treatment options cater to unique needs within the livestock sector, with antibiotics providing quick relief and vaccines offering sustainable protection against future outbreaks. ### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Pharmaceutical & Biotechnology Companies (Fastest-Growing) In the South America brucellosis market, the distribution of market share among end-users reveals that hospitals and diagnostic centers dominate, holding the largest share due to their critical role in diagnosis and patient care. This segment benefits from increasing healthcare expenditures and a rising prevalence of infectious diseases, which drives the demand for accurate diagnostic facilities and services. Conversely, pharmaceutical and biotechnology companies are rapidly emerging, appealing to consumers with innovative solutions for brucellosis treatment and potential vaccine development. Growth trends within this segment are largely driven by advancements in medical technology and increasing awareness of brucellosis among the population. As public health initiatives grow, hospitals and diagnostic centers are strengthening their capacities to respond effectively to the disease. Meanwhile, the pharmaceutical and biotechnology companies are leveraging research and development to launch new therapies, leading to market expansion. Additionally, collaborative efforts between academic institutions and biotechnology firms are fostering innovation, further propelling growth in this segment. Hospitals & Diagnostic Centers (Dominant) vs. Pharmaceutical & Biotechnology Companies (Emerging) Hospitals and diagnostic centers represent the dominant force in the South America brucellosis market, characterized by their essential services in disease identification and patient management. Their established infrastructure and comprehensive diagnostic capabilities provide them a competitive edge. On the other hand, pharmaceutical and biotechnology companies are emerging players, focusing on novel treatments and vaccines. This segment is marked by robust R&D investments and strategic partnerships with academic institutes, enabling them to introduce effective therapies rapidly. The distinction between these segments illustrates a landscape where traditional healthcare meets innovative biopharmaceutical approaches, catering to the evolving needs of the market. ## Regional Market Share Analysis ### Brazil : Leading Market with Strong Growth Drivers Brazil holds a commanding 15.0% market share in the South American brucellosis market, valued at approximately $XX million. Key growth drivers include increasing livestock production, heightened awareness of animal health, and government initiatives aimed at disease control. Regulatory policies, such as mandatory vaccination programs, are enhancing demand trends, while robust infrastructure in agribusiness supports industrial development. ### Mexico : Strategic Initiatives Boosting Demand Mexico accounts for a 5.0% share of the brucellosis market in South America, valued at around $XX million. The growth is driven by rising livestock exports and government support for vaccination programs. Demand trends indicate a shift towards preventive healthcare in livestock, supported by regulatory frameworks that promote animal health. The government is also investing in veterinary services to combat brucellosis effectively. ### Argentina : Key Player in Livestock Health Argentina holds a 10.0% market share in the brucellosis sector, valued at approximately $XX million. The country's growth is fueled by its significant cattle ranching industry and stringent health regulations. Demand for brucellosis vaccines is increasing, driven by both domestic consumption and export requirements. Government initiatives focus on eradicating the disease, enhancing livestock health, and ensuring food safety. ### Rest of South America : Diverse Opportunities Across Regions The Rest of South America contributes a 2.88% share to the brucellosis market, valued at around $XX million. Growth is driven by localized agricultural practices and increasing awareness of animal health. Regulatory policies vary by country, but many governments are implementing vaccination campaigns. Infrastructure development is uneven, impacting market dynamics and access to veterinary services in rural areas. ## Competitive Benchmarking The brucellosis market exhibits a competitive landscape characterized by a blend of established players and emerging innovators. Key growth drivers include increasing awareness of zoonotic diseases, rising livestock health concerns, and the demand for effective vaccines and diagnostics. Major companies such as Zoetis Inc (US), Merck & Co Inc (US), and Boehringer Ingelheim GmbH (DE) are strategically positioned to leverage these trends. Zoetis Inc (US) focuses on innovation in vaccine development, while Merck & Co Inc (US) emphasizes partnerships to enhance its product portfolio. Boehringer Ingelheim GmbH (DE) is actively pursuing regional expansion, particularly in South America, to capture a larger market share. Collectively, these strategies shape a competitive environment that is increasingly dynamic and responsive to market needs.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains. The market structure appears moderately fragmented, with several key players influencing overall dynamics. This fragmentation allows for niche players to thrive, while larger companies consolidate their positions through strategic acquisitions and partnerships. The collective influence of these key players fosters a competitive atmosphere that encourages innovation and responsiveness to market demands. In October Zoetis Inc (US) announced the launch of a new brucellosis vaccine specifically designed for cattle, which is expected to enhance herd immunity and reduce transmission rates. This strategic move underscores Zoetis's commitment to innovation and positions the company as a leader in the development of effective solutions for livestock health. The introduction of this vaccine could potentially reshape vaccination protocols across South America, addressing a critical need in the region. In September Merck & Co Inc (US) entered into a strategic partnership with a local veterinary services provider in Brazil to enhance distribution channels for its brucellosis diagnostic kits. This collaboration is likely to improve accessibility and awareness of brucellosis testing, thereby increasing market penetration. By aligning with local expertise, Merck & Co Inc (US) demonstrates a keen understanding of regional market dynamics and the importance of localized strategies. In August Boehringer Ingelheim GmbH (DE) expanded its production facility in Argentina to meet the growing demand for brucellosis vaccines. This expansion not only signifies Boehringer's commitment to the South American market but also enhances its capacity to deliver timely solutions to livestock producers. The strategic importance of this move lies in its potential to strengthen supply chain reliability and responsiveness to local market needs. As of November current competitive trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics and treatment solutions. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to address complex challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability. Companies that can effectively leverage these trends will likely secure a competitive edge in the evolving market. ## Recent News & Developments The South America Brucellosis Market is witnessing significant developments, marked by heightened awareness and control measures across the region. The Brazilian government has intensified vaccination campaigns against Brucellosis to enhance livestock health and productivity, leading to enhanced market stability. Elanco continues to focus on the effectiveness of its vaccine solutions in combating livestock diseases, while Ceva Sante Animale is launching new brucellosis vaccination programs aimed at improving dairy cattle health in Argentina. In terms of mergers and acquisitions, Zoetis announced the acquisition of a leading South American animal health company in July 2023, a move aimed at bolstering its position in the region's brucellosis market. Additionally, Boehringer Ingelheim's recent collaboration with local agricultural agencies in Colombia, reported in September 2023, highlights the company’s dedication to addressing livestock diseases. The overall market value for companies like Merck Animal Health and Virbac has seen an upward trajectory due to increased livestock health initiatives, with a growing demand for effectively managing Brucellosis impacting the landscape of South America's animal health industry significantly. ## Report Scope | MARKET SIZE 2024 | 32.88(USD Million) | | --- | --- | | MARKET SIZE 2025 | 35.17(USD Million) | | MARKET SIZE 2035 | 69.01(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.97% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim GmbH (DE), Ceva Santé Animale (FR), Vetoquinol SA (FR), Heska Corporation (US), Elanco Animal Health Incorporated (US), Virbac SA (FR) | | Segments Covered | Species, Diagnosis, Treatment, End-User | | Key Market Opportunities | Emerging diagnostic technologies enhance detection and management of brucellosis, driving market growth opportunities. | | Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation in brucellosis diagnostics and treatment solutions. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the current valuation of the South America brucellosis market in 2024?** A: The market valuation was $32.88 Million in 2024. **Q: What is the projected market valuation for the South America brucellosis market by 2035?** A: The projected valuation for 2035 is $69.01 Million. **Q: What is the expected CAGR for the South America brucellosis market from 2025 to 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 6.97%. **Q: Which companies are the key players in the South America brucellosis market?** A: Key players include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim GmbH, and others. **Q: What are the main species segments in the South America brucellosis market?** A: Main species segments include Brucella abortus, Brucella melitensis, and Brucella suis, among others. **Q: What is the valuation range for Brucella abortus in the South America brucellosis market?** A: The valuation range for Brucella abortus is $10.0 - $20.0 Million. **Q: What diagnostic methods are utilized in the South America brucellosis market?** A: Diagnostic methods include serological tests, molecular techniques, and bone marrow biopsy, among others. **Q: What is the projected valuation for antibiotics in the treatment segment of the South America brucellosis market?** A: The projected valuation for antibiotics is $10.0 - $20.0 Million. **Q: Which end-users are significant in the South America brucellosis market?** A: Significant end-users include hospitals & diagnostic centers and pharmaceutical & biotechnology companies. **Q: What is the valuation range for vaccines in the treatment segment of the South America brucellosis market?** A: The valuation range for vaccines is $15.0 - $30.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-brucellosis-market-53595*